Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
August 22 2024 - 8:00AM
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage
biotechnology company pioneering the development of a novel class
of oncolytic immunotherapies, today announced that a late-breaking
abstract presenting the primary analysis of the IGNYTE
clinical trial has been selected for oral presentation at the
European Society for Medical Oncology (ESMO) Congress 2024 being
held September 13-17, 2024, in Barcelona.
Presentation Details:
Title: Primary efficacy, safety, and survival
data from the registration-intended cohort of patients with
anti-PD-1-failed melanoma from the IGNYTE clinical trial with RP1
combined with nivolumabPresentation Session Title:
Mini Oral Session - Melanoma and other skin
tumoursPresentation Number: LBA46Date and
Time: Sunday, September 15, 2024 at 3:45 – 3:50 p.m.
CESTSpeakers: Caroline Robert, MD, PhD, Gustave
Roussy Cancer Center
About RP1RP1 (vusolimogene oderparepvec) is
Replimune’s lead product candidate and is based on a proprietary
strain of herpes simplex virus engineered and genetically armed
with a fusogenic protein (GALV-GP R-) and GM-CSF, intended to
maximize tumor killing potency, the immunogenicity of tumor cell
death, and the activation of a systemic anti-tumor immune
response.
About Replimune Replimune
Group, Inc., headquartered in Woburn, MA, was founded in 2015 with
the mission to transform cancer treatment by pioneering the
development of a novel portfolio of oncolytic immunotherapies.
Replimune’s proprietary RPx platform is based on a potent HSV-1
backbone intended to maximize immunogenic cell death and the
induction of a systemic anti-tumor immune response. The RPx
platform is designed to have a unique dual local and systemic
activity consisting of direct selective virus-mediated killing of
the tumor resulting in the release of tumor derived antigens and
altering of the tumor microenvironment to ignite a strong and
durable systemic response. The RPx product candidates are expected
to be synergistic with most established and experimental cancer
treatment modalities, leading to the versatility to be developed
alone or combined with a variety of other treatment options. For
more information, please visit www.replimune.com.
Forward Looking StatementsThis press release
contains forward looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including
statements regarding the design and advancement of our clinical
trials, the timing and sufficiency of our clinical trial outcomes
to support potential approval of any of our product candidates, our
goals to develop and commercialize our product candidates, patient
enrollments in our existing and planned clinical trials and the
timing thereof, and other statements identified by words such as
“could,” “expects,” “intends,” “may,” “plans,” “potential,”
“should,” “will,” “would,” or similar expressions and the negatives
of those terms. Forward-looking statements are not promises or
guarantees of future performance, and are subject to a variety of
risks and uncertainties, many of which are beyond our control, and
which could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to generate positive clinical trial results for our product
candidates, the costs and timing of operating our in-house
manufacturing facility, the timing and scope of regulatory
approvals, the availability of combination therapies needed to
conduct our clinical trials, changes in laws and regulations to
which we are subject, competitive pressures, our ability to
identify additional product candidates, political and global macro
factors including the impact of the coronavirus as a global
pandemic and related public health issues and the Russian-Ukrainian
and Israel-Hamas political and military conflicts, and other risks
as may be detailed from time to time in our Annual Reports on Form
10-K and Quarterly Reports on Form 10-Q and other reports we file
with the Securities and Exchange Commission. Our actual results
could differ materially from the results described in or implied by
such forward-looking statements. Forward-looking statements speak
only as of the date hereof, and, except as required by law, we
undertake no obligation to update or revise these forward-looking
statements.
Investor Inquiries Chris BrinzeyICR
Westwicke339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Dec 2024 to Jan 2025
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Jan 2024 to Jan 2025